Bristol-Myers Squibb Co. (BMY)

48.16
NYSE : Health Technology
Prev Close 48.92
Day Low/High 48.15 / 49.06
52 Wk Low/High 44.30 / 65.89
Avg Volume 18.54M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 79.86B
EPS 3.00
P/E Ratio 16.25
Div & Yield 1.64 (3.27%)
The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft is to be bought for about $2 billion by DXC Technology.

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

The company expects revenue to jump 12% year over year.

What the Action Alerts Plus Portfolio Is Looking at This Week

What the Action Alerts Plus Portfolio Is Looking at This Week

Are you ready for the week? Action Alerts Plus's Zev Fima breaks down what the portfolio is watching.

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Giovanni Caforio, M.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

Bristol-Myers, Apple and the economy are some of the top stories on TheStreet.

Dow Drops More Than 600 Points on Apple Warning, China Fears

Dow Drops More Than 600 Points on Apple Warning, China Fears

All three major indices dropped more than 2% Thursday.

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Video: Jim's Daily Rundown for Thursday

Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's Thoughts on Bristol-Myers Deal

Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Why Jim Cramer Is Worried About Bristol-Myers Bid to Buy Celgene

Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

TheStreet Quant Rating: C+ (Hold)